Financial Statements and Highlights | Takeda Investor Relations

EN

glasses laying on a book with stock options

Financial Highlights

Loading feed metadata...

Sign up for our investors newsletter

Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet

Recent News

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

Continuation of the Stock Compensation Plan for Directors and the Stock Grant System for Company Management in Japan in 2025

Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

Takeda Announces Completion of Acquisition of Own Shares

Explore

Investor Events

Access our IR events calendar and recaps of past events

Our Pipeline

Learn more about our dynamic and diverse pipeline